← Back to headlines
Wall Street Anticipates Multi-Billion Dollar Debut for Lilly's Obesity Pill
Despite Novo Nordisk's current market lead, Wall Street analysts are projecting a multi-billion dollar debut for Eli Lilly's new obesity pill.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
